Stock RCE RECCE PHARMACEUTICALS LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Delayed Australian S.E.
Other stock markets
 20:26:32 2024-06-25 EDT 		5-day change 1st Jan Change
0.515 AUD -2.83% Intraday chart for Recce Pharmaceuticals Ltd -12.71% -3.74%
06-25 Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections CI
06-24 Recce Pharmaceuticals Secures Ethics Approval for Bacterial Skin Infection Study MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Recce Pharmaceuticals Receives Ethics Approval to Broaden RECCE® 327 Gel Trials Across all Topical Bacterial Skin Infections
AQ
Recce Pharmaceuticals Ltd. Receives Ethics Approval to Broaden RECCE 327 Gel Trials Across All Topical Bacterial Skin Infections
CI
Recce Pharmaceuticals Secures Ethics Approval for Bacterial Skin Infection Study
MT
Recce Pharmaceuticals Announces Addition of RECCE® 327 to The World Health Organization’s List of Antibacterial Products in Clinical Development
AQ
Recce Pharmaceuticals Announces Addition of RECCE® 327 to the World Health Organization?S List of Antibacterial Products in Clinical Development
CI
Recce Pharmaceuticals' RECCE 327 Added to WHO's List of Antibacterial Products in Clinical Development
MT
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial
AQ
Recce Pharmaceuticals Completes Dosing in Urosepsis Rapid Infusion Clinical Trial
MT
Recce Pharmaceuticals' synthetic approach to combatting AMR
AQ
Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
AQ
Recce Pharmaceuticals Ltd Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
CI
Recce Pharmaceuticals doses highest cohort in phase I/II UTI/Urosepsis trial
AQ
Recce Pharmaceuticals Doses First Patient in Urosepsis Rapid Infusion Clinical Trial
MT
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
AQ
Recce Pharmaceuticals Reports Positive Preclinical Data of Recce® 327 in Lung Infection Pilot Study
CI
Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study
MT
Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration
CI
Recce Pharmaceuticals completes global patent portfolio
AQ
Recce Pharmaceuticals Obtains China Patent for Anti-Infectives
MT
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RCE Stock
  4. News Recce Pharmaceuticals Ltd